NOK 4.58
(-0.43%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 9.77 Million NOK | -517.23% |
2022 | 11.64 Million NOK | 125.75% |
2021 | 5.15 Million NOK | -2.94% |
2020 | 5.31 Million NOK | -56.55% |
2019 | 12.23 Million NOK | 36.66% |
2018 | 8.95 Million NOK | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | 2.79 Million NOK | 0.0% |
2024 Q1 | 2.79 Million NOK | 38.02% |
2023 Q4 | 2.02 Million NOK | 0.0% |
2023 FY | -48.59 Million NOK | -517.23% |
2023 Q1 | 1.2 Million NOK | -69.52% |
2023 Q3 | 2.02 Million NOK | 0.0% |
2023 Q2 | - NOK | -100.0% |
2022 Q4 | 3.93 Million NOK | 0.0% |
2022 FY | 11.64 Million NOK | 125.75% |
2021 FY | 5.15 Million NOK | -2.94% |
2020 FY | 5.31 Million NOK | -56.55% |
2019 FY | 12.23 Million NOK | 36.66% |
2018 FY | 8.95 Million NOK | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Aqua Bio Technology ASA | 607.92 Thousand NOK | -1507.692% |
ArcticZymes Technologies ASA | 113.01 Million NOK | 91.352% |
BerGenBio ASA | 354 Thousand NOK | -2660.902% |
Hofseth BioCare ASA | 29.87 Million NOK | 67.287% |
PCI Biotech Holding ASA | 2.99 Million NOK | -226.876% |
Thor Medical ASA | - NOK | -Infinity% |
Ultimovacs ASA | -2.76 Million NOK | 453.092% |